Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)

NCT02780128 is registered in ClinicalTrials.gov with Yael P Mosse as lead sponsor.

NCT NCT02780128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
Lead sponsor
Yael P Mosse
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2016
Completion date
August 31, 2022
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neuroblastoma